DICE Therapeutics (DICE Therapeutics) FCF Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is DICE Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. DICE Therapeutics's Free Cash Flow for the three months ended in Jun. 2023 was $-30.41 Mil. DICE Therapeutics's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, DICE Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, DICE Therapeutics's current FCF Yield % is -4.13%.

The historical rank and industry rank for DICE Therapeutics's FCF Margin % or its related term are showing as below:

During the past 4 years, the highest FCF Margin % of DICE Therapeutics was -299.20%. The lowest was -3556.44%. And the median was -2413.33%.

DICE's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

DICE Therapeutics FCF Margin % Historical Data

The historical data trend for DICE Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DICE Therapeutics FCF Margin % Chart

DICE Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

FCF Margin %

-299.20

-2,413.33

-3,556.44

DICE Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
FCF Margin %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of DICE Therapeutics's FCF Margin %

For the Biotechnology subindustry, DICE Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DICE Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DICE Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where DICE Therapeutics's FCF Margin % falls into.

DICE Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

DICE Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-66.559	/	0
	=	%

DICE Therapeutics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-30.405	/	0
	=	%

DICE Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of DICE Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

DICE Therapeutics (DICE Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 East Jamie Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.dicetherapeutics.com

DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.

Executives

Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
John R. Jacobsen	officer: CSO	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Scott M. Robertson	officer: CFO & CBO	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Lu Timothy	officer: CMO	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Kevin Judice	director, officer: CEO	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Lisa Bowers	director	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Mittie Doyle	director	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Michael P. Rubin	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Shaan-chirag C Gandhi	director	NORTHPOND VENTURES, 7500 OLD GEORGETOWN ROAD, BETHESDA MD 20814
Northpond Ventures Ii, Lp	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Stephen Zachary	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902